20 results about "Drug taking" patented technology

The invention relates to the technical field of biological medicines, in particular to application of hsacirc0008126 in prevention and treatment of senile osteoporosis. The invention provides the circular RNA hsacirc0008126 which can be used for regulating and controlling the mesenchymal stem cell osteogenesis and adipogenic differentiation, the mechanism of the circular RNA hsacirc0008126 on the mesenchymal stem cell osteogenesis and adipogenic differentiation is different from that of the prior art, the medicine taking the circular RNA hsacirc0008126 as the target spot can be used for treating and / or preventing osteoporosis, and the circular RNA hsacirc0008126 has important application value.

The invention provides a medical drug intelligent rental cabinet system integrating identity verification and drug use safety early warning, and relates to the technical field of water turbine blade detection, and the system comprises an identity verification module which is used for carrying out the identity information collection and validity verification of a drug taking person; the medication information matching module is used for matching the identity information of the personnel passing the identity verification with pre-stored medication prescription information; the drug use safety early warning module is used for analyzing the drug use risk based on the matching result and generating early warning information; dependence of traditional manual registration and verification is thoroughly eliminated, non-sensitization and high efficiency of identity verification and precision of medicine matching are achieved, adaptation limitation of single-mode verification is avoided, manual judgment errors are eradicated through automatic data retrieval, it is ensured that each time of medicine taking corresponds to legal personnel and compliant prescriptions, and the accuracy of medicine taking is improved. And a safety defense line for medicine access is built from the source.

The invention discloses a reversible multi-nozzle needleless injection ampoule with a turbulent flow mixing function, and belongs to the technical field of medical instruments. Due to the design of the integrally-formed nozzle base, all dynamic sealing interfaces which may fail under high pressure are eliminated, so that the pressure resistance of the ampoule is greatly improved, and the service life of the ampoule is greatly prolonged; according to intelligent switching of the injection modes, a user can switch between the deep precise injection mode and the superficial broad-spectrum coverage mode through simple rotating operation, unprecedented clinical adaptability is given to the ampoule, clear tactile / auditory feedback is achieved in the switching process, the clinical adaptability is high, and operation is convenient and fast. The multifunctional injector integrates the functions of injection mode switching, liquid medicine mixing and front-end medicine taking, and the clinical adaptability and operation convenience are improved.

The application relates to application of a medicine taking ACLY gene as an action target in preparation of a medicine for preventing and treating vascular calcification, and belongs to the technical field of biological medicine. In order to solve the problem that effective clinical means for treating vascular calcification is lacked at present, the application provides application of a medicine taking ACLY gene as an action target in preparation of a medicine for preventing and treating vascular calcification, the transcription or translation of the ACLY gene of vascular smooth muscle cells is efficiently and specifically inhibited, or the expression or activity of the ACLY protein of the vascular smooth muscle cells is efficiently and specifically reduced, the osteogenic differentiation of smooth muscle is reduced, the deposition of hydroxyapatite in the vascular media is reduced, and the progress of vascular calcification is alleviated. The medicine for preventing and treating vascular calcification is prepared on the basis of inhibition of the ACLY of vascular smooth muscle, has important clinical application potential for vascular calcification treatment, and can provide a new treatment option for patients with vascular calcification.

The invention provides a rapid drug taking screening method and device.The rapid drug taking screening method comprises the steps that skin spectral characteristics of a to-be-recognized user are obtained, and the skin spectral characteristics comprise at least one of skin structure characteristics, skin fingerprint characteristics and skin component characteristics; wherein the skin structure characteristics refer to the characteristics of macromolecular structures of the skin, the skin fingerprint characteristics refer to the characteristics of residual traces of foreign molecules on the skin, and the skin component characteristics refer to the characteristics of the content of inherent components on the skin; acquiring trace element characteristics of the user to be identified, wherein the trace element characteristics comprise at least one of the following characteristics: a zinc element concentration characteristic, an iron element concentration characteristic and a copper element concentration characteristic; and carrying out fusion analysis on the skin spectral features and the trace element features, and judging whether the to-be-identified user has a drug taking behavior or not based on a preset identification model. According to the embodiment of the invention, the screening accuracy and screening efficiency of the drug taking behavior can be effectively improved.

The application discloses a controlled-release pharmaceutical composition and a preparation method and application thereof. The controlled-release pharmaceutical composition comprises a quick-release part and an enteric sustained-release part; the quick-release part comprises a first active ingredient, and the enteric sustained-release part comprises a second active ingredient and a sustained-release material; the first active ingredient or the second active ingredient is selected from racemic indobufen or S-indobufen or a pharmaceutically acceptable salt thereof; and the sustained-release material is selected from one or a combination of any number of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, xanthan gum, sodium alginate, sodium carboxymethyl cellulose, acrylic resin, carbomer or polyethylene oxide. The composition can realize once-a-day oral administration, reduces the frequency of drug taking of a patient, and improves the drug taking compliance of the patient; the preparation process is simple, short in time, low in energy consumption, and suitable for industrial production; the influence of food on product burst release is greatly reduced, the stimulation and adverse reactions of the product on the gastrointestinal tract are reduced, and in particular, the risk of gastric hemorrhage is reduced.

The present application relates to a kind of sustained-release acyclovir tablets and its preparation process, belong to the technical field of medicine.The acyclovir tablet provided by the present application has immediate-release layer and sustained-release layer, immediate-release layer can be quickly released, rapidly increase the blood concentration in human body;Sustained-release layer has multi-stage drug release characteristics, it includes three kinds of sustained-release particles, which can effectively delay, positioning release drug, constantly supplement the blood concentration in body, maintain stable blood concentration, can effectively sustain release up to about 12h, and can maintain relatively stable blood concentration within 12 hours, reduce the frequency of drug taking, improve patient compliance, suitable for the patient with herpes simplex virus infection who needs long-term treatment.

The invention discloses a drug-resistant main protease inhibitor with stable metabolism and application thereof in preparation of antiviral drugs. In the main protease inhibitor, a group C not only can be effectively combined with an active pocket of main protease, but also the combination mainly depends on the 163rd amino acid site of the main protease; meanwhile, the group C is relatively difficult to oxidize, so that the main protease inhibitor can show basically consistent inhibitory activity to both mutant strains and wild strains, viruses do not generate drug resistance to the main protease inhibitor, and the main protease inhibitor can tolerate liver drug enzyme metabolism, has excellent drug-resistant activity and metabolic stability, and can be used for preparing the main protease inhibitor. In use, a liver drug enzyme inhibitor does not need to be used cooperatively, and reduction of self liver function decline and toxic and side effects caused by medicine taking is facilitated. In addition, the group A not only can further improve the inhibitory activity of the main protease inhibitor on the main protease, but also can enhance the anti-drug resistance activity and metabolic stability of the main protease inhibitor; and the ring B mainly plays a role in further improving the inhibitory activity of the main protease inhibitor on the main protease.

The invention discloses a drug-resistant main protease inhibitor with stable metabolism and application thereof in preparation of antiviral drugs. In the main protease inhibitor, a group C not only can be effectively combined with an active pocket of main protease, but also the combination mainly depends on the 163rd amino acid site of the main protease; meanwhile, the group C is relatively difficult to oxidize, so that the main protease inhibitor can show basically consistent inhibitory activity to both mutant strains and wild strains, viruses do not generate drug resistance to the main protease inhibitor, and the main protease inhibitor can tolerate liver drug enzyme metabolism, has excellent drug-resistant activity and metabolic stability, and can be used for preparing the main protease inhibitor. In use, a liver drug enzyme inhibitor does not need to be used cooperatively, and reduction of self liver function decline and toxic and side effects caused by medicine taking is facilitated. In addition, the group A not only can further improve the inhibitory activity of the main protease inhibitor on the main protease, but also can enhance the anti-drug resistance activity and metabolic stability of the main protease inhibitor; and the ring B mainly plays a role in further improving the inhibitory activity of the main protease inhibitor on the main protease.

The invention discloses an application of a Prmt5 gene and a substance for regulating expression of the Prmt5 gene in preparation of a product for treating cerebellar ataxia. The invention belongs to the technical field of biology, and particularly relates to an application of a Prmt5 gene and a substance for regulating expression of the Prmt5 gene in preparation of a product for treating cerebellar ataxia. The invention provides an application of a drug taking a Prmt5 gene as a drug action target in preparation of a drug for treating or preventing cerebellar ataxia related diseases and an application of a product for reducing formation of inhibitory synapses.

The application discloses a metabolically stable anti-drug-resistant main protease inhibitor and application thereof in preparation of antiviral drugs. In the main protease inhibitor, the group C can be effectively combined with the active pocket of the main protease, and the combination mainly depends on the 163th amino acid site of the main protease; meanwhile, the group C is difficult to be oxidized, so that the main protease inhibitor can exhibit basically consistent inhibitory activity to both mutant strains and wild strains, the virus cannot produce drug resistance to the main protease inhibitor of the application, and the main protease inhibitor has excellent anti-drug resistance activity and metabolic stability, and does not need to be used in combination with a liver enzyme inhibitor when used, which is favorable for reducing self-liver function reduction and toxic side effects caused by drug taking. In addition, the group A can further improve the inhibitory activity of the main protease inhibitor to the main protease, and can enhance the anti-drug resistance activity and metabolic stability of the main protease inhibitor; and the B ring mainly plays a role in further improving the inhibitory activity of the main protease inhibitor to the main protease.

The invention discloses a preparation method of a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, and relates to the technical field of medicines, the pharmaceutical composition comprises a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong According to the preparation method of the pharmaceutical composition for treating the cardiovascular and cerebrovascular diseases, multi-target and multi-layer treatment is realized by comprehensively applying six methods of traditional Chinese medicine, and the cardiovascular and cerebrovascular functions are conditioned fundamentally; the medicine composition has a strong synergistic effect, and can be used for dissolving thrombus and dredging collaterals, repairing vascular endothelium and promoting myocardial cell regeneration; the treatment mode is safe, and western medicine operation wounds and side effects caused by long-term medicine taking are avoided; oral administration and intravenous administration are combined, so that the drug absorption and action persistence are enhanced; the traditional Chinese medicine external treatment method can be matched to further improve the curative effect and realize metabolic balance.

The invention discloses an application of SLC25A13 as a prognostic marker and a therapeutic target for predicting lung adenocarcinoma. Through large-scale and multi-queue systematic analysis, the SLC25A13 is identified as a key gene significantly related to survival of a lung adenocarcinoma patient, the defects that a traditional small sample screening or empirical target spot discovery method is poor in repeatability and high in false positive rate are overcome, and the SLC25A13 serving as a prognostic marker has higher reliability and clinical transformation potential; in addition, high expression of SLC25A13 in the invention prompts poor prognosis; prognostic risk assessment is performed based on detection of the expression level (or genetic markers related to expression) of the SLC25A13 gene or protein thereof, a relatively objective and quantitative molecular typing means is provided, and different products can be derived based on the SLC25A13. Comprising but not limited to a detection kit for prognosis prediction, a prognosis scoring model or system based on the marker, and a therapeutic drug taking SLC25A13 as a target spot.

The application belongs to the technical field of medical management, and discloses a comprehensive and collaborative management system and method for narcotic and psychotropic drugs, which comprises a safe storage monitoring unit, a drug taking operation unit and a drug data insight unit. The safe storage monitoring unit is used for deploying a deformable magnetic fluid sealing mechanism on the upper part of a narcotic and psychotropic drug box, and controlling the shape change of the magnetic fluid through an electromagnetic signal. When an unauthorized opening behavior is monitored, the topological structure is triggered to deform and automatically lock the drug box. The drug taking operation unit is used for providing a drug taking path guide through the AR interface of the drug box, and combining a multi-frequency LED array to indicate the target drug storage bin for drug taking. The drug data insight unit is used for collecting narcotic and psychotropic drug consumption data and narcotic and psychotropic drug prescription data from the information storage terminal of the drug storage bin, and constructing a narcotic and psychotropic drug consumption atlas through the narcotic and psychotropic drug consumption data. In the process of drug management, omnidirectional safety protection, intelligent operation, accurate analysis and optimization are realized, and the management efficiency, accuracy, safety and intelligent level of narcotic and psychotropic drugs are greatly improved.

The invention provides a brain-computer interface-based hypertensive drug dynamic monitoring system and a brain-computer interface-based hypertensive drug dynamic monitoring method, designs a novel hypertensive drug dynamic monitoring mechanism, and analyzes the drug effect by mixing the electroencephalogram signal, the blood pressure signal and the drug taking time to form a multi-modal signal. A series of optimization settings continue to be matched from the aspect of details, so that through multi-modal fusion, dynamic modeling, personalized optimization and clinical closed loop, the system comprehensively surpasses the prior art in the aspects of monitoring dimension, decision depth and function integration, and through collaborative analysis of nerve-blood pressure-autonomic nerve, the accuracy of the system is improved. The normal form transformation of hypertension treatment from symptomatic administration to nerve-body fluid-blood vessel coordinated regulation is promoted, and the accuracy, individuation and safety of hypertension drug monitoring are remarkably improved.

The invention discloses application of a PTPRO gene in preparation of a product for treating memory deficiency related diseases, and belongs to the technical field of biological medicines. The amino acid sequence of the PTPRO gene is shown as SEQ ID NO.1. A PTPRO gene knockout mouse is constructed, the influence of PTPRO on learning and memory functions is explored by taking the mouse as a tool, and a molecular mechanism of PTPRO playing a role is further studied, so that a drug taking the PTPRO gene as an action target can efficiently and specifically interfere with transcription or translation of the PTPRO gene on the basis of interference of the PTPRO gene, and the effect of the PTPRO gene on learning and memory functions is further studied. Further, protein expression of the PTPRO gene is promoted or enhanced, and the effect of improving memory is achieved. The invention provides a new target and a new direction for clinical treatment and prevention of learning and memory defect related diseases.

The application provides a lysozyme-modified adhesive butyrate microcapsule preparation method and application thereof, and belongs to the technical field of medicine manufacturing. The microcapsule has a core-shell structure, the outer layer material is a thiolated pectin microsphere, and the inside is wrapped with sodium butyrate-loaded egg white lysozyme nanoparticles. The application proves through in-vitro and in-vivo experiments that the microcapsule has good gastrointestinal stability and colon targeting, can prolong the intestinal retention time, improve the effective concentration of butyric acid in the colon, shield the bad smell, significantly improve the intestinal homeostasis related to colitis, and improve the drug taking acceptance. The application provides a green, safe and efficient technical solution for the preparation of exogenous butyrate drugs.

The invention provides a preparation method and application of a lysozyme modified adhesive butyrate microcapsule, and belongs to the technical field of medicine manufacturing. The microcapsule is of a core-shell structure, an outer-layer material is sulfhydrylated pectin microspheres, and sodium butyrate loaded egg white lysozyme nanoparticles are wrapped in the outer-layer material. In-vitro and in-vivo experiments prove that the microcapsule shows good gastrointestinal stability and colon targeting property, can prolong the residence time of the intestinal tract, improve the effective concentration of butyric acid in the colon and shield unpleasant odor, and also improves the drug administration acceptance degree while remarkably improving the intestinal steady state related to colitis. The invention provides a green, safe and efficient technical scheme for preparing the exogenous butyrate medicine.

The application belongs to the technical field of information processing, and particularly relates to a liver transplantation drug guidance system based on multiple expert diagnosis opinions and intelligent reasoning; the system comprises a data management module, a diagnosis analysis module, a drug suggestion module and a feedback module; the data management module is used for collecting user health index data and multiple expert diagnosis opinions, and storing medical literature; the diagnosis analysis module is used for generating user diagnosis information according to information of the data management module; the drug suggestion module is used for generating a drug scheme according to information of the data management module, user diagnosis information and feedback information of the feedback module; and the feedback module is used for obtaining feedback information, including user health index data after drug taking and expert feedback information; the application overcomes the limitations of traditional drug guidance methods, and realizes more scientific, objective and accurate postoperative drug guidance for liver transplantation.